Optum

Clinical Assistant

A clinical decision support (CDS) solution delivering personalized, evidence-based and value-based guidance at the point of care

Venu - Recommenders	-Type II Diabetes				Optu	n						alam Assist	••• Ø ***
Delrio, Mario Ot-Jun 2055 (85 ye) M	Active Problems 7 1904	~ ^{A4}	lva Vindu		Orug Alla	rgins	~	Anarance (ui mage				
Ofinical Facts	<		ion recomm		~								
A3C trend	8.8% >												
A3C target	7%. >	0	mpolišng needi kty	0.001103/14	ight in Earlin	a so Abodikoo	mia, et al	se GLP L BANKS	good efficacy fo	rweight ions	67.966796, w	Non also der	NO ENDINE OV
Нак менте территрукаттій	No 2	1 1	tiestaleadya	n Vetformie	- Cn Gelddin								
Taking 120M mods	Yes 3	Review car	ant active di	abotic mad	Gratines								
Number of T25H meds	* >	Action		Vedentier			Prof	_	threes	. 0		otto O	
Has met/08945% contrainede	ation No >	Action							efferig			018 0	enes co
Hart ASCI/D	No 3			Januariat	- metrosano		0.0xmg 882	y2000.mg PD)	- ejs (🔊 🕄	ଅ 🕄 🏺
ASCND risk	53.6% >		-						14	·			
10.17	No 3	Medication											
Has CKD	184 P	Action	Medication	0	teres o o	Drug Cime	0 8	o:	Benefits O	the O		40	Notate CC
BACK trend	405 mg/g >			-		-		,				irrated cost	U-1005+8Q
eOfficiend	48.8 es(/eis/178e* >		degladec Tresko		Contract Name	Insulin		Notest .		¶° 😘		dan Inf	aiy
Hypophyseen's rick is a factor	No >											watedcost	0-1005+80
ENG trend	36-Siger >	0.000	glargine (assister)		(B) Highly Favane	Insulin		(C)		👎 🖄		realized cost	647
Number of contraind leads second rendered and close	n 10											watedoost	
			glargine		0	Insulin		•		42 B.		Harn Post	0 100 1+10 (04)
			Ditte		Higtly Favares			Highest			* a	T arr 2015	
		-	gingine-ytp		0	bade		0		60 (Q			0 100 1+10
			Sengre		Highly Favores	baulin		Ngheat		. U.	T (8	dan Pot	airy
											D	mated cost	

Image does not depict real patients and is for illustrative purposes only.

Clinical Assistant simplifies the process for providers to follow evidence-based guidelines, helping to improve quality and reduce cost of care. With real-time drug pricing and personalized patient recommendations, providers and patients become allies in shared decision-making. This solution results in enhanced therapy adherence and better clinical outcomes.

Clinical Assistant helps deliver better care



\$

Price transparency at the point of care

Real-time prescription benefits offer a clear view of medication costs to both providers and patients, helping them choose the most effective and affordable treatment option.



Ready-made CDS

Optum medical informaticists transform narrative guidelines into code and ensure the content remains current and accurate. This helps clinical and IT staff focus on other priorities.

Medication recommender

This EHR-integrated application within the provider ambulatory encounter workflow presents real-time, personalized medication recommendations at the point of care. Patient-specific pricing details provide cost transparency to the patient and provider.

• Menu Optum			T2DM Ev	ridence-Based Medication	Ordering				O HEL			
Evidence-based factors		Evidence	-based medication re	commendations								
Patient Facts		Based on the	American Diabetes Associati									
DELRIO. Mario	06-3un-1973 (47 yo) M	Mattinenie as	first line therapy (eGFR should be m									
Active Problems	T2DH 7 3											
Active Medications	• >	Configurat u	Competing need to control weight and minimise hypologycenia, choose GUP-1 RA with good efficacy for weight loss or SQUTD, which also demonstrates CV safety:									
Drug Altergies	NKDA								anon none -			
Clinical Facts		Review curre	t active diabetic medications									
	22-Mar-2023 8.5 % 3	Action	Modication		Details	Efficacy O		Benefits O Risk	.0			
ALC Trend	22-01al-2023 83% 3	· DESCONTINU		c.	50mg/1000mg PO BID	0		¥20 40	P			
A1C Target		_	(SITagliptin-metFORMIN)			Highest						
Has Seven Hyperglycemia	na 3 Nas 2	· DESCONTINU	SU glimepiride		2mg PG QD			20	îa 👻			
Taking T2DH Mede Number of T2DH Hede	3 3					(right						
Has metFORNIN Contraindication		Order medica							a			
Has ASCVD	Yes 2								1.			
ASCVD Risk	085.2	+ GLP-1 RA	on guideline Redication	2 Details O	: Efficacy 0	: Cost O		Denefits O Ris				
Has INF			Indication	0.75mg SubQ QVIK		Patient Cost		Benefits D 101				
Has CKD	Tes 2		dulaglutide) O	F/U in: 4 weeks	High	Fucient Cost.		1 El				
UACR frend	#12 mg/g)	1000										
aGTR Trand	48.8 at / and / 1.71at	executide)		2mg flubQ QWK 8/U in: 4 yeaks	(B) High	Patient Cost		a 💔				
Hypoglycervia Risk is a Pacitor	No. 7	· capes	Iyetta	5moj SušQ 810	8	Patient Cost		2 4				
Weight Gain is a Factor	Yes.)		exenatide)	F/U in: 2 wooks	High			er				
DHI Trand	29.5 30/101 3		rictoze	0.6mg SubQ QD	8	Patient Cost		40 W SI				
Number of Centraindications to Recomme	ersted Hed Classes e 3		Breglutide) O	P/U in: 2 weeks	High							
			Adlyxin Tixisenatide)	somey SubQ QD F/U in: 2 weeks	(B)	Patient Cost		Ø 1				

Image does not depict real patients and is for illustrative purposes only.

Performance and analytics dashboards

Provide clinical and executive leaders with real-time data on utilization and impact of medication recommender.

"

I needed this yesterday. I think it's going to be great for patients and fantastic for providers. The tool is very intuitive and easy to use.

- Physician, mid-sized health system

To learn more about Clinical Assistant:

Visit our product page

Scan the code





optum.com

Optum is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2025 Optum, Inc. All rights reserved. WF17059558 04/25



Clinical Assistant presents evidencebased recommendations for these high-value conditions, with more in development:

- Type 2 diabetes mellitus
- Heart failure
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Hypertension
- Hyperlipidemia
- Migraine